• Something wrong with this record ?

Evolution of Advanced Chronic Lymphoid Leukemia Unveiled by Single-Cell Transcriptomics: A Case Report

P. Ostasov, H. Robertson, P. Piazza, A. Datta, J. Apperley, L. Houdova, D. Lysak, M. Holubova, K. Tesarova, VS. Caputo, I. Barozzi,

. 2020 ; 10 (-) : 584607. [pub] 20201030

Language English Country Switzerland

Document type Case Reports

Persistent link   https://www.medvik.cz/link/bmc21001863

Genetic and transcriptional heterogeneity of Chronic lymphocytic leukaemia (CLL) limits prevention of disease progression. Longitudinal single-cell transcriptomics represents the state-of-the-art method to profile the disease heterogeneity at diagnosis and to inform about disease evolution. Here, we apply single-cell RNA-seq to a CLL case, sampled at diagnosis and relapse, that was treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) and underwent a dramatic decrease in CD19 expression during disease progression. Computational analyses revealed a major switch in clones' dominance during treatment. The clone that expanded at relapse showed 17p and 3p chromosomal deletions, and up-regulation of pathways related to motility, cytokine signaling and antigen presentation. Single-cell RNA-seq uniquely revealed that this clone was already present at low frequency at diagnosis, and it displays feature of plasma cell differentiation, consistent with a more aggressive phenotype. This study shows the benefit of single-cell profiling of CLL heterogeneity at diagnosis, to identify clones that might otherwise not be recognized and to determine the best treatment options.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21001863
003      
CZ-PrNML
005      
20210126092731.0
007      
ta
008      
210105s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fonc.2020.584607 $2 doi
035    __
$a (PubMed)33194728
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Ostasov, Pavel $u Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia. Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
245    10
$a Evolution of Advanced Chronic Lymphoid Leukemia Unveiled by Single-Cell Transcriptomics: A Case Report. / $c P. Ostasov, H. Robertson, P. Piazza, A. Datta, J. Apperley, L. Houdova, D. Lysak, M. Holubova, K. Tesarova, VS. Caputo, I. Barozzi,
520    9_
$a Genetic and transcriptional heterogeneity of Chronic lymphocytic leukaemia (CLL) limits prevention of disease progression. Longitudinal single-cell transcriptomics represents the state-of-the-art method to profile the disease heterogeneity at diagnosis and to inform about disease evolution. Here, we apply single-cell RNA-seq to a CLL case, sampled at diagnosis and relapse, that was treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) and underwent a dramatic decrease in CD19 expression during disease progression. Computational analyses revealed a major switch in clones' dominance during treatment. The clone that expanded at relapse showed 17p and 3p chromosomal deletions, and up-regulation of pathways related to motility, cytokine signaling and antigen presentation. Single-cell RNA-seq uniquely revealed that this clone was already present at low frequency at diagnosis, and it displays feature of plasma cell differentiation, consistent with a more aggressive phenotype. This study shows the benefit of single-cell profiling of CLL heterogeneity at diagnosis, to identify clones that might otherwise not be recognized and to determine the best treatment options.
655    _2
$a kazuistiky $7 D002363
700    1_
$a Robertson, Henry $u Imperial BRC Genomics Facility, Imperial College London, London, United Kingdom.
700    1_
$a Piazza, Paolo $u Imperial BRC Genomics Facility, Imperial College London, London, United Kingdom.
700    1_
$a Datta, Avik $u Imperial BRC Genomics Facility, Imperial College London, London, United Kingdom.
700    1_
$a Apperley, Jane $u Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.
700    1_
$a Houdova, Lucie $u NTIS, Faculty of Applied Science, University of West Bohemia, Pilsen, Czechia.
700    1_
$a Lysak, Daniel $u Department of Haematology and Oncology, University Hospital Pilsen, Pilsen, Czechia.
700    1_
$a Holubova, Monika $u Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia. Department of Haematology and Oncology, University Hospital Pilsen, Pilsen, Czechia.
700    1_
$a Tesarova, Katerina $u Faculty of Medicine in Pilsen, Institute of Medical Genetics, Charles University in Prague and Faculty Hospital, Pilsen, Czechia.
700    1_
$a Caputo, Valentina S $u Hugh & Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.
700    1_
$a Barozzi, Iros $u Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
773    0_
$w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 10, č. - (2020), s. 584607
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33194728 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210126092726 $b ABA008
999    __
$a ind $b bmc $g 1614044 $s 1122147
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 10 $c - $d 584607 $e 20201030 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
LZP    __
$a Pubmed-20210105

Find record

Citation metrics

Archiving options